Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial
2015 · The Lancet Oncology · 293 citations
https://doi.org/10.1016/s1470-2045(14)71181-7
A
Arun Rajan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
264
Papers
7.3K
Citations
46
h-index
95
i10-index
Arun Rajan is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Myasthenia Gravis and Thymoma & Lung Cancer Treatments and Mutations & Pituitary Gland Disorders and Treatments. The author has an h-index of 46, co-authored 225 publications.
ORCID: 0000-0003-2776-3385Papers by this author
worksAvelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
2017 · The Lancet Oncology · 292 citations
https://doi.org/10.1016/s1470-2045(17)30239-5
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
2020 · Cell Reports Medicine · 167 citations
https://doi.org/10.1016/j.xcrm.2020.100007
Mutations of epigenetic regulatory genes are common in thymic carcinomas
2014 · Scientific Reports · 127 citations
https://doi.org/10.1038/srep07336
Liquid biopsy epigenomic profiling for cancer subtyping
2023 · Nature Medicine · 102 citations
https://doi.org/10.1038/s41591-023-02605-z
Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models
2022 · Nature Communications · 99 citations
https://doi.org/10.1038/s41467-022-29517-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat